newsfilter
← Latest News
GlobeNewswire·

Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants

ACRS
  • Aclaris Therapeutics, Inc. priced an underwritten offering of 7,785,714 common stock shares at $3.50 per share.
  • The company also issued pre-funded warrants for 6,500,000 shares at $3.49999 per warrant to certain investors.
  • All shares, warrants, & proceeds are being sold directly by Aclaris.
  • Investors participating in the offering include TCGX, RA Capital Management, Invus, & a large mutual fund.
  • Gross proceeds from the offering are expected to be approximately $50.0 million before deducting underwriting discounts & expenses.
  • The offering is scheduled to close on October 28, 2026, subject to customary closing conditions.
  • Leerink Partners, Piper Sandler, Cantor, & LifeSci Capital are acting as joint bookrunning managers.
  • The offering was made pursuant to a Form S-3 shelf registration statement filed with the SEC on August 6, 2026.
  • Copies of the prospectus supplement & accompanying prospectus are available from Leerink Partners, Piper Sandler, & Cantor Fitzgerald.